NCT00327535 - A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Anemia

Interventions

DRUG

Darbepoetin alfa

According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)

DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

6.3 micrograms/kg every 3 weeks

DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

9 micrograms/kg every 3 weeks

DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

12 micrograms/kg every 3 weeks

Trial Locations (68)

852

Hong Kong

1090

Vienna

1145

Vienna

1160

Vienna

1529

Budapest

2650

Edegem

3233

Mátraháza

4000

Liège

4020

Linz

4064

Milton

4400

Nyíregyháza

5020

Salzburg

5037

Kurralta Park

6772

Deszk

8001

Székesfehérvár

9300

Aalst

11527

Athens

11619

Tallinn

14076

Caen

16132

Genova

17007

Girona

21075

Hamburg

21079

Dijon

22045

Hamburg

27100

Pavia

28034

Madrid

28041

Madrid

28046

Madrid

28100

Novara

33600

Pessac

37045

Legnago

38320

San Cristóbal de La Laguna

48100

Ravenna

50009

Zaragoza

51003

Tartu

54290

Trier

56429

Thessaloniki

57001

Thessaloniki

69126

Heidelberg

69437

Lyon

69495

Pierre-Bénite

71013

San Giovanni Rotondo

71110

Heraklion

75571

Paris

76137

Karlsruhe

82131

Gauting

93009

Bobigny

97448

Saint-Pierre

VIC 3165

East Bentleigh

M4C 3E7

Toronto

M5G 2M9

Toronto

639 00

Brno

500 05

Hradec Králové

708 52

Ostrava

180 01

Prague

00029

Helsinki

41 110

Larissa

Unknown

Hong Kong

07100

Sassari

85-326

Bydgoszcz

82-300

Elblag

05-400

Otwock

60-569

Poznan

26-617

Radom

53-439

Wroclaw

87-800

Włocławek

08003

Barcelona

08036

Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY